RD Fund thesis is generally focused on therapeutic companies that range from nearing a pre-IND to clinically staged programs focused on inherited retinal disease (IRD) conditions and dry AMD. The Fund is geographically agnostic, and has an initial investment allocation range typically between $2M and $5M. The RD Fund is unique in that it can leverage the full weight of the Foundation Fighting Blindness’s knowledge and resources including: natural history studies, My Retinal Tracker® Registry, world-class scientific advisory board and clinical consortium. As a result, the RD Fund leverages both internal resources, and investment capital to attract additional investors and is open to using financial instruments including convertible notes, equity, fixed multiple return on investments, and/or royalties, with a preference for ground floor equity investments. The RD Fund currently has ongoing investments in SparingVision, Nacuity Pharmaceuticals, ProQR Therapeutics, CheckedUp, Nayan Therapeutics, Vedere Bio, and Atsena Therapeutics.